Can This Drug Strengthen Pfizer Sales?

Since the proposed transaction with AstraZeneca looks like it's going to fall through, one of the big things that Pfizer  investors will want to know is simple: What's next?

One good way for an investor to look at a pharma company's future is by examining its pipeline. And once a drug in that pipeline looks interesting, it's important to be aware of the market size, competitors, and possible issues with safety and efficacy.

In this video, from Where the Money Is, the Motley Fool's investing show, health care analysts Michael Douglass and David Williamson lay out Pfizer's  opportunity with bococizumab, a new PCSK9 drug, and note the issues ahead for Pfizer and competitors like Sanofi and Regeneron's  alirocumab.

Top dividend stocks for the next decade -- is Pfizer one?
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

The article Can This Drug Strengthen Pfizer Sales? originally appeared on

David Williamson owns shares of Pfizer. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story